Bilir, BülentEkiz Bilir, BetülTakir, M.Sertbaş, Y.Akıncı, C.M.Çiftçi, H.2022-05-112022-05-1120152149-2042https://doi.org/10.5222/MMJ.2015.083https://hdl.handle.net/20.500.11776/8781The effect of ezetimibe monothrepy on decreasing lipid molecules has been widely studied in the literature so far, but scarce number of clinical studies have evaluated the effect of this pharmacological agent on lipoprotein-(a). In our study, we aimed to evaluate the effect of ezetimibe monotherapy on lipoprotein-(a) and other lipid parameters with clinical aspects. Ezetimibe monotherapy for three months was used for the hyperlipidemic patients admitted to our internal medicine outpatient clinic. Lipoprotein-(a) total cholesterol, low-density lipoprotein, very-low-density lipoprotein, high-density lipoprotein, and triglyceride levels before and after ezetimibe therapy were subjected to biochemical analysis. In addition to descriptive statistics of data, paired-t-test and Pearson Correlation analysis were used. All results were evaluated within 95% confidence interval and considered as statistically siginificant if p values were lower than 0.05. After treatment lipoprotein-(a), total cholesterol, and LDL-cholesterol levels decreased but the changes in very low-density lipoprotein, high-density lipoprotein, and triglyceride levels were not statistically siginificant (p>0.05). In the treatment of hyperlipidemia, ezetimibe can be an adjunct to other antihyperlipidemic drugs or an alternative monotherapy. © 2015, Logos Medical Publishing. All rights reserved.tr10.5222/MMJ.2015.083info:eu-repo/semantics/openAccessAtherosclerosisEzetimibeLipoprotein-(a)Article30283882-s2.0-85044137843Q4